Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose, Foradil Aerolizer, High Dose, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Phoenix, Arizona • Encinitas, California • Los Angeles, California + 26 more

Conditions: Asthma
Interventions: Symbicort pMDI, budesonide pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 12,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 160
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more

Conditions: Diabetes Mellitus, Asthma, Pulmonary Disease, Chronic Obstructive
Interventions: Human Insulin Inhalation Powder, injected insulin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 36
States / cities: Montgomery, Alabama • Burbank, California • Greenbrae, California + 33 more

Conditions: Asthma
Interventions: Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250, Formoterol fumarate 10; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 62
States / cities: Pell City, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more

Conditions: Asthma
Interventions: lebrikizumab, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 70
States / cities: Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more

Conditions: Asthma
Interventions: QAV680, QAV680 Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Cypress, California • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Asthma
Interventions: Placebo, BI 54903, Fluticasone propionate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more

Conditions: Asthma
Interventions: Lebrikizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,068 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 66
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 54 more

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more

Conditions: Asthma
Interventions: tiotropium-bromide, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more

Conditions: Asthma
Interventions: ONO-6950, Montelukast, Placebo; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 6 more

Conditions: Asthma
Interventions: Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 116
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Torrance, California • Ocala, Florida • Owensboro, Kentucky + 8 more

Conditions: Asthma
Interventions: Beclomethasone dipropionate, Placebo, Albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 1,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 94
States / cities: Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more

Conditions: Asthma
Interventions: Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 29
States / cities: Birmingham, Alabama • Mission Viejo, California • Orange, California + 26 more

Conditions: Nasal Polyps
Interventions: Depemokimab (GSK3511294), Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Tucson, Arizona • Roseville, California • New Haven, Connecticut + 11 more

Conditions: Asthma
Interventions: albuterol HFA (Armstrong's), albuterol HFA (Proventil HFA), HFA placebo; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Mobile, Alabama • Huntington Beach, California • Long Beach, California + 34 more

Conditions: Asthma
Interventions: Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more

Conditions: Mild Atopic Asthma
Interventions: BITS7201A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 17
States / cities: Los Angeles, California • Rolling Hills Estates, California • Clearwater, Florida + 14 more

Conditions: Asthma
Interventions: BI 671800, Fluticasone propionate placebo, Fluticasone propionate, BI 671800 Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Tucson, Arizona • Cypress, California • Los Angeles, California + 34 more

Conditions: Asthma
Interventions: Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Placebo DPI, Albuterol MDI 90 mcg/inh; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 4
States / cities: San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more

Conditions: Asthma
Interventions: Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 23
States / cities: Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more

Conditions: Asthma
Interventions: E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 Placebo, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg, epinephrine inhalation aerosol, CFC propelled, E004 (epinephrine inhalation aerosol), 160 mcg; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: San Jose, California • Stockton, California

Search by objective public record fields.

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

BI 671800 ED in Steroid-naive Asthmatic Patients

Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.